BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Ependymoma Treatment Market – Forecast to 2030,’ thoroughly examines the Ependymoma Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Failed Back Surgery Syndrome Treatment Market – Forecast to 2030,’ thoroughly examines the Failed Back Surgery Syndrome Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Glioma Treatment Market – Forecast to 2030,’ thoroughly examines the Glioma Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Helicobacter Pylori Infections Treatment Market – Forecast to 2030,’ thoroughly examines the Helicobacter Pylori Infections Treatment industry to provide essential data & information for the targeted readers.

ZyVersa Therapeutics, Inc. and Larkspur Health Acquisition Corp. are pleased to announce that Larkspur has refiled with the U.S. Securities and Exchange Commission their proxy/registration statement on Form S-4 in connection with the business combination agreement between Larkspur and ZyVersa previously announced on July 20, 2022.

BioNJ, the voice of the life sciences industry in New Jersey, announced the launch of its Health Equity in Clinical Trials Initiative.

Immune Therapeutics, Inc today announced the appointment of Louis Salomonsky to the Company’s Board of Directors.

On behalf of the more than 6 million Americans living with Alzheimer’s disease and their families, the Alzheimer’s Association enthusiastically welcomes the positive topline data reported by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.

The latest market analysis report published by Reports and Data, titled ‘Global Hypertrophic Cardiomyopathy Market – Forecast to 2030,’ thoroughly examines the Hypertrophic Cardiomyopathy industry to provide essential data & information for the targeted readers.

PineTree Therapeutics and Professors Jason Evans and Nurit Haspel at University of Massachusetts Boston have received capital funding this summer from the Massachusetts Life Sciences Center Bits and Bytes program to accelerate the efforts of PineTree Therapeutics’ next generation biotherapeutics development.